PMID- 22310598
OWN - NLM
STAT- MEDLINE
DCOM- 20120524
LR  - 20161125
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 44
IP  - 1
DP  - 2012 Jan
TI  - Cyclosporine or tacrolimus: which is the better partner for myfortic or cellcept?
PG  - 137-9
LID - 10.1016/j.transproceed.2011.12.023 [doi]
AB  - BACKGROUND: Mycophenolic acid (MPA) pharmacokinetics using the mycophenolate 
      mofetil (CellCept) formulation are known to differ between patients receiving 
      tacrolimus (FK) or cyclosporine (CyA), but only limited data exist concerning 
      concomitant use of FK or CyA with enteric-coated mycophenolate sodium (EC-MPS; 
      Myfortic). This retrospective study compared the drug interactions with the 
      mycophenolic acid blood levels using different immunosuppressants and their 
      relation to graft survival. PATIENTS AND METHODS: We studied MPA levels in 
      posttransplant sera from 298 renal transplant recipients. RESULTS: Patients 
      receiving immunosuppression with CyA + Myfortic showed 94% at 5- and 10-year 
      graft survivals, which were better than CyA + CellCept (75%, 63%). This 
      combination suppressed posttransplant human leukocyte antigen (HLA) antibody 
      development significantly (P = .03) with higher MPA levels. CONCLUSION: Patients 
      immunosuppressed with CyA + Myfortic showed higher MPA levels and lower 
      posttransplant HLA antibody development as well as the best graft survival. CyA + 
      Myfortic or FK + Cellcept may be better combinations.
CI  - Copyright (c) 2012 Elsevier Inc. All rights reserved.
FAU - Lee, P-C
AU  - Lee PC
AD  - Department of Surgery, National Cheng-Kung University Medical College and 
      Hospital, Tainan, Taiwan. pochang@mail.ncku.edu.tw
FAU - Chang, S-S
AU  - Chang SS
FAU - Shieh, S-C
AU  - Shieh SC
FAU - Wu, Z-C
AU  - Wu ZC
FAU - Wang, W-M
AU  - Wang WM
FAU - Wang, J-D
AU  - Wang JD
FAU - Hung, C-J
AU  - Hung CJ
FAU - Lin, Y-J
AU  - Lin YJ
FAU - Chou, T-C
AU  - Chou TC
FAU - Chan, R-H
AU  - Chan RH
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (HLA Antigens)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Isoantibodies)
RN  - 83HN0GTJ6D (Cyclosporine)
RN  - HU9DX48N0T (Mycophenolic Acid)
RN  - WM0HAQ4WNM (Tacrolimus)
SB  - IM
MH  - Cyclosporine/*therapeutic use
MH  - Drug Interactions
MH  - Drug Monitoring
MH  - Drug Therapy, Combination
MH  - Graft Rejection/immunology/prevention & control
MH  - Graft Survival/drug effects
MH  - HLA Antigens/immunology
MH  - Histocompatibility/drug effects
MH  - Humans
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Isoantibodies/blood
MH  - *Kidney Transplantation/immunology
MH  - Mycophenolic Acid/*analogs & derivatives/blood/pharmacokinetics/therapeutic use
MH  - Retrospective Studies
MH  - Tacrolimus/*therapeutic use
MH  - Taiwan
MH  - Treatment Outcome
EDAT- 2012/02/09 06:00
MHDA- 2012/05/25 06:00
CRDT- 2012/02/08 06:00
PHST- 2012/02/08 06:00 [entrez]
PHST- 2012/02/09 06:00 [pubmed]
PHST- 2012/05/25 06:00 [medline]
AID - S0041-1345(11)01685-X [pii]
AID - 10.1016/j.transproceed.2011.12.023 [doi]
PST - ppublish
SO  - Transplant Proc. 2012 Jan;44(1):137-9. doi: 10.1016/j.transproceed.2011.12.023.